Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Change in Accured Expenses (2016 - 2025)

Organogenesis Holdings (ORGO) has 10 years of Change in Accured Expenses data on record, last reported at $8.9 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 171.63% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $10.4 million, up 13.28%, while the annual FY2025 figure was $10.4 million, 13.28% up from the prior year.
  • Change in Accured Expenses reached $8.9 million in Q4 2025 per ORGO's latest filing, down from $15.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $15.4 million in Q3 2025 and bottomed at -$11.9 million in Q4 2022.
  • Average Change in Accured Expenses over 5 years is $857000.0, with a median of $717000.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: crashed 18542.86% in 2021, then surged 582700.0% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $12.3 million in 2021, then crashed by 196.85% to -$11.9 million in 2022, then soared by 100.19% to $23000.0 in 2023, then skyrocketed by 14169.57% to $3.3 million in 2024, then soared by 171.63% to $8.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $8.9 million in Q4 2025, $15.4 million in Q3 2025, and -$5.9 million in Q2 2025.